{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:51:11Z","timestamp":1787187071226,"version":"build-2736575974"},"reference-count":65,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Ruxolitinib (Jakafi) is a Janus kinase 1 and 2 small molecule inhibitor that the Food and Drug Administration approved for myelofibrosis and polycythemia vera. It has been expanded to off-label treatment for a variety of dermatologic conditions, with several clinical trials ongoing. A review of available studies and cases of off-label uses was performed to guide clinicians seeking evidence on the efficacy of this Janus kinase inhibitor for dermatologic disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      PubMed\/MEDLINE, EMBASE, Scopus, and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      databases were searched with the term \u201cruxolitinib,\u201d and results were manually reviewed to identify published data on off-label uses of ruxolitinib. Studies included are structured by quality of evidence available.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ruxolitinib may have utility in the treatment of atopic dermatitis, psoriasis, and vitiligo, with data from open-label and randomized trials supporting efficacy of topical formulations. Evidence of utility for alopecia areata is mixed and differs depending on topical versus oral form. Evidence for numerous other conditions is available through case reports and case series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is growing evidence supporting potential off-label use of oral and topical ruxolitinib for a wide range of skin conditions. There are several ongoing investigations of ruxolitinib use in dermatology that will undoubtedly better define its efficacy and appropriate use in dermatology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/der.0000000000000658","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T11:50:03Z","timestamp":1610625003000},"page":"164-172","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Off-label Studies on the Use of Ruxolitinib in Dermatology"],"prefix":"10.1177","volume":"32","author":[{"given":"Kyle","family":"Tegtmeyer","sequence":"first","affiliation":[{"name":"From the, *Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Ravi","sequence":"additional","affiliation":[{"name":"From the, *Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Zhao","sequence":"additional","affiliation":[{"name":"From the, *Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan J.","family":"Maloney","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Lio","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine"},{"name":"Medical Dermatology Associates of Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"e_1_3_1_2_2","unstructured":"Jakafi (Ruxolitinib) [package insert]. Wilmington DE: Incyte Corporation; 2020."},{"issue":"6","key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/2040620712459746","article-title":"Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis","volume":"3","author":"Harrison C","year":"2012","unstructured":"Harrison C, , Vannucchi AM. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Ther Adv Hematol, 2012; 3(6):341\u2013354.","journal-title":"An update for clinicians. Ther Adv Hematol"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.13167.1"},{"issue":"3","key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.12788\/j.sder.2018.041","article-title":"JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases","volume":"37","author":"Kahn J","year":"2018","unstructured":"Kahn J, , Deverapalli SC, , Rosmarin D. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases. Semin Cutan Med Surg, 2018; 37(3):198\u2013208.","journal-title":"Semin Cutan Med Surg"},{"key":"e_1_3_1_6_2","first-page":"1","article-title":"Off-label studies on tofacitinib in dermatology: a review","author":"Tegtmeyer K","year":"2019","unstructured":"Tegtmeyer K, , Zhao J, , Maloney NJ, et al. Off-label studies on tofacitinib in dermatology: a review. J Dermatolog Treat, 2019; 1\u201311.","journal-title":"J Dermatolog Treat"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24976"},{"issue":"5","key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jdcr.2018.01.001","article-title":"Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib","volume":"4","author":"Aboul-Fettouh N","year":"2018","unstructured":"Aboul-Fettouh N, , Nijhawan RI. Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib. JAAD Case Rep, 2018; 4(5):455\u2013457.","journal-title":"JAAD Case Rep"},{"issue":"17","key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"e120750","DOI":"10.1172\/jci.insight.120750","article-title":"Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma","volume":"3","author":"Abikhair Burgo M","year":"2018","unstructured":"Abikhair Burgo M, , Roudiani N, , Chen J, et al. Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma. JCI Insight, 2018; 3(17):e120750.","journal-title":"JCI Insight"},{"issue":"10","key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jdcr.2019.06.038","article-title":"A photo-distributed papulopustular eruption and multiple squamous cell carcinomas in a patient on ruxolitinib","volume":"5","author":"Khanna U","year":"2019","unstructured":"Khanna U, , Richardson V, , Hexner E, et al. A photo-distributed papulopustular eruption and multiple squamous cell carcinomas in a patient on ruxolitinib. JAAD Case Rep, 2019; 5(10):895\u2013897.","journal-title":"JAAD Case Rep"},{"issue":"5","key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.21873\/invivo.11653","article-title":"Aggressive Merkel cell carcinoma after Janus kinase inhibitor ruxolitinib for polycythemia vera","volume":"33","author":"Rastrelli M","year":"2019","unstructured":"Rastrelli M, , Ferrazzi B, , Tropea S, et al. Aggressive Merkel cell carcinoma after Janus kinase inhibitor ruxolitinib for polycythemia vera. In Vivo, 2019; 33(5):1667\u20131669.","journal-title":"In Vivo"},{"key":"e_1_3_1_12_2","first-page":"75","article-title":"Jakafi (ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia vera","volume":"8","author":"Raedler LA","year":"2015","unstructured":"Raedler LA. Jakafi (ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia vera. Am Health Drug Benefits, 2015; 8:75\u201379.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.018"},{"key":"e_1_3_1_14_2","unstructured":"EndNote X8.2. 2014. Philadelphia PA United States: Clarivate Analytics."},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.3163\/1536-5050.104.3.014"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"issue":"2","key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jaad.2019.10.016","article-title":"Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study","volume":"82","author":"Olsen EA","year":"2020","unstructured":"Olsen EA, , Kornacki D, , Sun K, et al. Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study. J Am Acad Dermatol, 2020; 82(2):412\u2013419.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/ijd.14192","article-title":"Treatment of alopecia universalis with topical Janus kinase inhibitors\u2014a double blind, placebo, and active controlled pilot study","volume":"57","author":"Bokhari L","year":"2018","unstructured":"Bokhari L, , Sinclair R. Treatment of alopecia universalis with topical Janus kinase inhibitors\u2014a double blind, placebo, and active controlled pilot study. Int J Dermatol, 2018; 57(12):1464\u20131470.","journal-title":"Int J Dermatol"},{"issue":"2","key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000494613","article-title":"Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study","volume":"235","author":"Almutairi N","year":"2019","unstructured":"Almutairi N, , Nour TM, , Hussain NH. Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study. Dermatology, 2019; 235(2):130\u2013136.","journal-title":"Dermatology"},{"issue":"15","key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan J","year":"2016","unstructured":"Mackay-Wiggan J, , Jabbari A, , Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight, 2016; 1(15):e89790.","journal-title":"JCI Insight"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.042"},{"issue":"4","key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani N","year":"2015","unstructured":"Punwani N, , Burn T, , Scherle P, et al. Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor. Br J Dermatol, 2015; 173(4):989\u2013997.","journal-title":"Br J Dermatol"},{"issue":"4","key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani N","year":"2012","unstructured":"Punwani N, , Scherle P, , Flores R, et al. Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol, 2012; 67(4):658\u2013664.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.02.049"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jaad.2018.08.040","article-title":"Ruxolitinib for the treatment of severe alopecia areata","volume":"80","author":"Liu LY","year":"2019","unstructured":"Liu LY, , King BA. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol, 2019; 80:566\u2013568.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart CB","year":"2017","unstructured":"Bayart CB, , DeNiro KL, , Brichta L, et al. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol, 2017; 77:167\u2013170.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/ijd.13598","article-title":"Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring","volume":"56","author":"Vandiver A","year":"2017","unstructured":"Vandiver A, , Girardi N, , Alhariri J, et al. Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring. Int J Dermatol, 2017; 56:833\u2013835.","journal-title":"Int J Dermatol"},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/jdv.15383","article-title":"Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata","volume":"33","author":"Gordon SC","year":"2019","unstructured":"Gordon SC, , Abudu M, , Zancanaro P, et al. Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata. J Eur Acad Dermatol Venereol, 2019; 33:e156\u2013e157.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2927"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417716363"},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris JE","year":"2016","unstructured":"Harris JE, , Rashighi M, , Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol, 2016; 74:370\u2013371.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jdcr.2020.02.007","article-title":"Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient","volume":"6","author":"Peterson DM","year":"2020","unstructured":"Peterson DM, , Vesely MD. Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient. JAAD Case Rep, 2020; 6:257\u2013259.","journal-title":"JAAD Case Rep"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow BG","year":"2016","unstructured":"Craiglow BG, , Tavares D, , King BA. Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol, 2016; 152:490\u2013491.","journal-title":"JAMA Dermatol"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.23871","article-title":"Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia","volume":"90","author":"Pieri L","year":"2015","unstructured":"Pieri L, , Guglielmelli P, , Vannucchi AM. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol, 2015; 90:82\u201383.","journal-title":"Am J Hematol"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000479722"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jid.2016.02.015","article-title":"JAK1\/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus","volume":"136","author":"Wenzel J","year":"2016","unstructured":"Wenzel J, , van Holt N, , Maier J, et al. JAK1\/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus. J Invest Dermatol, 2016; 136:1281\u20131283.","journal-title":"J Invest Dermatol"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-018-0519-6"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.02.006"},{"issue":"6","key":"e_1_3_1_40_2","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau L","year":"2018","unstructured":"Ladislau L, , Su\u00e1rez-Calvet X, , Toquet S, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain, 2018; 141(6):1609\u20131621.","journal-title":"Brain"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy255"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1412997"},{"key":"e_1_3_1_43_2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib","volume":"13","author":"King B","year":"2017","unstructured":"King B, , Lee AI, , Choi J. Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib. J Invest Dermatol, 2017; 13:951\u2013954.","journal-title":"J Invest Dermatol"},{"key":"e_1_3_1_44_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13256-017-1304-5","article-title":"Ruxolitinib found to cause eyelash growth: a case report","volume":"11","author":"Song J","year":"2017","unstructured":"Song J, , Song A, , Palmares T, et al. Ruxolitinib found to cause eyelash growth: a case report. J Med Case Rep, 2017; 11:189.","journal-title":"J Med Case Rep"},{"key":"e_1_3_1_45_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2019.03.016","article-title":"Treatment of pembrolizumab-induced cutaneous lesions with ruxolitinib","volume":"113","author":"Chen CY","year":"2019","unstructured":"Chen CY, , Chiu CF, , Bai LY. Treatment of pembrolizumab-induced cutaneous lesions with ruxolitinib. Eur J Cancer, 2019; 113:69\u201371.","journal-title":"Eur J Cancer"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0756"},{"key":"e_1_3_1_47_2","first-page":"504","article-title":"Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor","volume":"179","author":"Nasifoglu S","year":"2018","unstructured":"Nasifoglu S, , Heinrich B, , Welzel J. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol, 2018; 179:504\u2013505.","journal-title":"Br J Dermatol"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.07.015"},{"key":"e_1_3_1_49_2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10875-019-00645-0","article-title":"Efficacy and adverse events during Janus kinase inhibitor treatment of SAVI syndrome","volume":"39","author":"Volpi S","year":"2019","unstructured":"Volpi S, , Insalaco A, , Caorsi R, et al. Efficacy and adverse events during Janus kinase inhibitor treatment of SAVI syndrome. J Clin Immunol, 2019; 39:476\u2013485.","journal-title":"J Clin Immunol"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01535"},{"key":"e_1_3_1_51_2","doi-asserted-by":"crossref","first-page":"108273","DOI":"10.1016\/j.clim.2019.108273","article-title":"Baricitinib experience on STING-associated vasculopathy with onset in infancy: a representative case from Turkey","volume":"212","author":"Balci S","year":"2020","unstructured":"Balci S, , Ekinci RMK, , de Jesus AA, et al. Baricitinib experience on STING-associated vasculopathy with onset in infancy: a representative case from Turkey. Clin Immunol, 2020; 212:108273.","journal-title":"Clin Immunol"},{"key":"e_1_3_1_52_2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.2340\/00015555-3006","article-title":"Efficacy of oral ruxolitinib in a patient with refractory chronic spontaneous urticaria","volume":"98","author":"Fukunaga A","year":"2018","unstructured":"Fukunaga A, , Ito M, , Nihigori C. Efficacy of oral ruxolitinib in a patient with refractory chronic spontaneous urticaria. Acta Derm Venereol, 2018; 98:904\u2013905.","journal-title":"Acta Derm Venereol"},{"key":"e_1_3_1_53_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40364-016-0056-5","article-title":"Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis","volume":"4","author":"Yacoub A","year":"2016","unstructured":"Yacoub A, , Prochaska L. Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis. Biomark Res, 2016; 4:2.","journal-title":"Biomark Res"},{"key":"e_1_3_1_54_2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1056\/NEJMoa1905633","article-title":"JAK inhibitor therapy in a child with inherited USP18 deficiency","volume":"382","author":"Alsohime F","year":"2020","unstructured":"Alsohime F, , Martin-Fernandez M, , Temsah MH, et al. JAK inhibitor therapy in a child with inherited USP18 deficiency. N Engl J Med, 2020; 382:256\u2013265.","journal-title":"N Engl J Med"},{"key":"e_1_3_1_55_2","volume-title":"A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis","author":"ClinicalTrials.gov","year":"2019","unstructured":"ClinicalTrials.gov. A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis. Bethesda, MD: National Library of Medicine; 2019."},{"key":"e_1_3_1_56_2","volume-title":"A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis","author":"ClinicalTrials.gov","year":"2017","unstructured":"ClinicalTrials.gov. A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis. Bethesda, MD: National Library of Medicine; 2017."},{"key":"e_1_3_1_57_2","volume-title":"TRuE AD2\u2014An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis","author":"ClinicalTrials.gov","year":"2018","unstructured":"ClinicalTrials.gov. TRuE AD2\u2014An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis. Bethesda, MD: National Library of Medicine; 2018."},{"key":"e_1_3_1_58_2","volume-title":"TRuE AD1\u2014An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis","author":"ClinicalTrials.gov","year":"2018","unstructured":"ClinicalTrials.gov. TRuE AD1\u2014An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis. Bethesda, MD: National Library of Medicine; 2018."},{"key":"e_1_3_1_59_2","volume-title":"Topical Ruxolitinib Lichen Planus","author":"ClinicalTrials.gov","year":"2018","unstructured":"ClinicalTrials.gov. Topical Ruxolitinib Lichen Planus. Bethesda, MD: National Library of Medicine; 2018."},{"key":"e_1_3_1_60_2","volume-title":"A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis","author":"ClinicalTrials.gov","year":"2009","unstructured":"ClinicalTrials.gov. A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis. Bethesda, MD: National Library of Medicine; 2009."},{"key":"e_1_3_1_61_2","volume-title":"Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis","author":"ClinicalTrials.gov","year":"2008","unstructured":"ClinicalTrials.gov. Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis. Bethesda, MD: National Library of Medicine; 2008."},{"key":"e_1_3_1_62_2","volume-title":"A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis","author":"ClinicalTrials.gov","year":"2008","unstructured":"ClinicalTrials.gov. A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis. Bethesda, MD: National Library of Medicine; 2008."},{"key":"e_1_3_1_63_2","volume-title":"Topical Ruxolitinib for the Treatment of Vitiligo","author":"ClinicalTrials.gov","year":"2016","unstructured":"ClinicalTrials.gov. Topical Ruxolitinib for the Treatment of Vitiligo. Bethesda, MD: National Library of Medicine; 2016."},{"key":"e_1_3_1_64_2","volume-title":"A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo","author":"ClinicalTrials.gov","year":"2017","unstructured":"ClinicalTrials.gov. A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo. Bethesda, MD: National Library of Medicine; 2017."},{"key":"e_1_3_1_65_2","volume-title":"Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)","author":"ClinicalTrials.gov","year":"2019","unstructured":"ClinicalTrials.gov. Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2). Bethesda, MD: National Library of Medicine; 2019."},{"key":"e_1_3_1_66_2","volume-title":"Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)","author":"ClinicalTrials.gov","year":"2019","unstructured":"ClinicalTrials.gov. Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1). Bethesda, MD: National Library of Medicine; 2019."}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0000000000000658","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1097\/DER.0000000000000658","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0000000000000658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:05:45Z","timestamp":1777399545000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1097\/DER.0000000000000658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6,1]]}},"alternative-id":["10.1097\/DER.0000000000000658"],"URL":"https:\/\/doi.org\/10.1097\/der.0000000000000658","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}